Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries

Eva Depuydt1,2*, Sarah Y. Broeckx1, Koen Chiers3, Marco Patruno4, Laura Da Dalt4, Luc Duchateau5, Jimmy Saunders6, Frederik Pille2, Ann Martens2, Lore Van Hecke1 and Jan H. Spaas1,6

The use of mesenchymal stem cells (MSCs) for the treatment of equine tendon disease is widely investigated because of their regenerative and immunomodulatory potential. However, questions have been raised concerning the immunogenic properties of allogeneic MSCs. Therefore, two studies were conducted to assess the safety of equine allogeneic peripheral blood-derived tenogenic primed MSCs (tpMSCs). The objective was to evaluate if a single and repeated tpMSC administration induced a cellular and humoral immune response in horses suffering from tendon injuries. Horses enrolled in the first study (n = 8) had a surgically induced superficial digital flexor tendon core lesion and were treated intralesionally with tpMSCs. Before and after treatment the cellular immunogenicity was assessed by modified mixed lymphocyte reactions. The humoral immune response was investigated using a crossmatch assay. Presence of anti-bovine serum albumin (BSA) antibodies was detected via ELISA. Horses enrolled in the second study (n = 6) suffered from a naturally occurring tendon injury and were treated twice with tpMSCs. Blood was collected after the second treatment for the same immunological assays. No cellular immune response was found in any of the horses. One out of eight horses in the first study and none of the horses in the second study had anti-tpMSC antibodies. This particular horse had an equine sarcoid and further investigation revealed presence of antibodies against sarcoid cells and epithelial-like stem cells before treatment, which increased after treatment. Additionally, formation of antibodies against BSA was observed. These findings might indicate a non-specific immune response generated after treatment. Serum from the other horses revealed no such antibody formation. These two studies showed that the administration of tpMSCs did not induce
INTRODUCTION

Autologous equine mesenchymal stem cells (MSCs) are widely used in clinical studies as regenerative treatment for musculoskeletal diseases in horses (1–5). Harvesting and cultivating autologous MSCs is an invasive, expensive and time-consuming process with disadvantageous effects of donor age and disease state on MSC functionality (6–10). Therefore, recent research focusses on allogeneic treatments offering an off-the-shelf, quality controlled, standardized MSC product (11–16). The use of MSCs for the treatment of equine tendon disease is investigated because of their regenerative and immunomodulatory potential. However, their tenogenic properties and regenerative effects could be compromised by the inflammatory environment of the acute tendon injury (17). Moreover, although not in horses, ectopic bone formation has been reported in mice and rabbits after administration of bone marrow-derived MSCs (BM-MSCs) into acute tendon lesions (18–21). In order to overcome these disadvantageous effects, MSCs can be tenogenic primed before clinical application (22).

Our research group has administered allogeneic tenogenic primed and chondrogenic induced MSCs in horses suffering from tendon (23–25) and joint (26–29) injuries respectively, reporting minimal local adverse effects. However, controversy exists on the immunogenic properties and thus the safe use of allogeneic MSC treatments (30, 31). The induction of the humoral and cellular immune responses after major histocompatibility complex (MHC)-mismatched MSC treatment has been described (32–34) and could result in potential immunological abnormalities following repeated administration. Because it has been reported that priming the MSCs could induce a higher MHC-I and MHC-II expression (34, 35), the immunogenicity of allogeneic tenogenic primed MSCs should be investigated, emphasizing the importance of current research.

The most widely used in vitro test to investigate the cellular immunogenicity of MSCs is the mixed lymphocyte reaction (MLR) (36). Previously published MLR results in horses of allogeneic BM-MSCs co-cultured with equine peripheral blood-derived mononuclear cells (PBMCs) described no induction of the host’s cellular immune response (13, 37). However, Schnabel et al., reported that MHC-II positive BM-MSCs cause significantly increased responder PBMC proliferation and that the immunogenicity of MHC-II negative MSC treatments should also be taken under consideration (32). For this reason, the immunogenicity of an allogeneic MSC treatment should be taken under consideration when evaluating MSC treatment options (38, 39).

In addition to a cellular immune response, administration of allogeneic MSCs could result in a humoral immune response by the recipient. Antibody production following an allogeneic MSC administration has been reported in the horse (15, 33, 34, 40, 41). The possible production of anti-MSC antibodies must be taken under consideration when performing repeated MSC injections. Although repeated injection of allogeneic MSCs has already been described in dogs (42) and horses (34, 41, 43), few studies have investigated the presence of anti-MSC antibodies (15, 33, 34, 42). Therefore, the current study evaluates the cellular and humoral response against a single and a repeated dose of equine allogeneic peripheral blood-derived tenogenic primed MSCs in horses with tendon injuries.

Another aspect of an immunological concern to consider is that a (semi)annual vaccination of horses [against equine influenza, rhinopneumonitis and tetanus for example (44)] can lead to the induction of an immune response to xenoproteins present in the vaccine. Most viral vaccines contain bovine serum albumin (BSA), the major component of fetal bovine serum (FBS), which can result in the development of anti-BSA antibodies (45). Because the tpMSCs are cultured in medium supplemented with FBS, it is important to correctly differentiate between antibody responses directed toward the tpMSCs and those directed toward a xenoprotein in which the tpMSCs are cultivated. Therefore, the detection of anti-BSA antibodies is also included in the current immunogenicity investigation.

The objective of this investigation is to evaluate the cellular and humoral immunogenicity of a single and repeated intratendinous injection of equine allogeneic tenogenic primed peripheral blood-derived MSCs (tpMSCs) in horses suffering from tendon injuries.

MATERIALS AND METHODS

Horses

The blood collection from the horses (EC_2017_001) including the blood collection from the donor horses (EC_2016_003) was approved by an independent ethics committee approved by the Flemish Government (permit number: LA1700607). The research of the present study was in accordance with

Abbreviations: 7-AAD, 7-aminoactinomycin D; BM, Bone marrow; BPV, Bovine papillomavirus; BSA, Bovine serum albumin; DMEM, Dulbecco’s modified Eagle medium; EpSC, Epithelial-like stem cell; FBS, Fetal bovine serum; FCCA, Flow cytometric crossmatch assay; HBSS, Hank’s balanced salt solution; MHC, Major histocompatibility complex; MLR, Mixed lymphocyte reaction; MSCs(s), Mesenchymal stem cell(s); PBMCs(s), Peripheral blood mononuclear cell(s); SDFT, Superficial digital flexor tendon; tpMSCs(s), Tenogenic primed mesenchymal stem cell(s).
national and international animal welfare regulations (Directive 2001/82/EC as amended, Belgian animal welfare legislation (KB 29/05/2013), Directive 2010/63/EU and EMEA/ Config/816/00-Final).

For the first study, eight warmblood horses (four geldings and four mares; age ranged between 3 and 12 years) with a surgically induced superficial digital flexor tendon (SDFT) core lesion enrolled in a previous study performed by our group received a single intrasional treatment with a proprietary formulation of $3 \times 10^6$ equine allogeneic tenogenic primed mesenchymal stem cells (tpMSCs) (16). To assess the cellular immune response, 9 mL of whole blood was collected aseptically from the vena jugularis into sterile ethylenediaminetetraacetic acid (EDTA) tubes before treatment and 16 weeks after treatment. For the investigation of the humoral immune response, blood was collected before and 2 weeks after tpMSC administration in serum clot activator blood collection tubes.

For the second study, blood was collected 6 to 8 weeks after the second tpMSC treatment from six client-owned warmblood horses (two geldings, two mares and two stallions; age ranged between 8 and 19 years) suffering from naturally occurring tendon disease receiving a repeated intrasional tpMSC administration (time range of 7 to 9 weeks between the two tpMSC administrations). The treatment consisted of $3 \times 10^6$ tpMSCs for each injection. From these horses, peripheral blood was collected on a single occasion to reduce inter-test variation.

**Isolation and Tenogenic Priming of Mesenchymal Stem Cells**

Tenogenic primed MSCs were prepared from the peripheral blood from one adult donor horse and characterized as previously described (23, 47). Briefly, blood was collected aseptically from the vena jugularis in sterile EDTA tubes. After gradient centrifugation, the interphase was isolated, seeded and cultivated in culture medium [Dulbecco's modified Eagle medium low glucose (DMEM; Life Technologies) supplemented with FBS (Sigma-Aldrich)]. Subsequently, the MSCs were cultured until passage 5 and thoroughly characterized (i.e. viability, morphology, presence of cell surface markers, and trilmage differentiation) as previously described (47), prior of being frozen as intermediate cell stock. After characterization, cells were thawed, further cultivated and tenogenic primed by adding tenogenic growth factors to the culture medium. The specific growth factors and the markers used for characterization of the tenogenic priming cannot be disclosed due to company policies. At 80% confluency, the cells were trypsinized and resuspended at a concentration of $3 \times 10^6$ tpMSCs in 1 mL DMEM supplemented with 10% dimethyl sulfoxide (Sigma-Aldrich). The samples were cryopreserved at $-80^\circ$C until further use. For each treatment, tpMSCs were thawed, drawn into a syringe and injected intrasionally immediately after thawing. The donor horse was screened for equine pathogens as previously reported by our group (23) at Böse laboratory (Harsum, Germany).

**Immunophenotyping of MSCs Using Flow Cytometry**

To perform an immunophenotypic characterization of the MSCs, the expression of several markers was evaluated simultaneously by flow cytometry as previously described (47). Per series, MSCs were labeled using the following panel of primary antibodies: CD29-APC (clone TS2/16, Biologend), CD44-FITC (clone CVS18, Bio-Rad), CDS (clone DH24A, A&E Scientific), CD45-PE-Cy5.5 (clone F10-89-4, Bio-Rad) and MHC-II-PE (clone CVS20, Bio-Rad). For the CD90 detection, a secondary anti-mouse IgM-PE-Cy7 antibody was used (clone RMM-1, Biologend). A minimum of 10,000 counts were acquired using a BD FACSCanto II flow cytometer (BD Biosciences). In addition, cells were incubated in parallel with or without isotype-specific murine IgG1-APC (clone TS2/16, Biologend), IgG1-FITC (clone MOPC-21, Biologend), IgM-PE-Cy7 (clone RMM-1, Biologend), IgG2a-PE-Cy5.5 (clone MOPC-173) and IgG1-PE (clone MOPC-21, Biologend) to establish the background signal.

**Modified Mixed Lymphocyte Reaction**

Whole blood was centrifuged, and the buffy coat was collected and diluted in Hank's balanced salt solution (HBSS, Life Technologies). Next, the suspension was layered upon an equal volume of Percoll and the interphase was collected after gradient centrifugation. PBMCs were washed and resuspended in HBSS to a concentration of $1 \times 10^6$ PBMCs/mL. Subsequently, the PBMCs were labeled with carboxyfluorescein succinimidyl ester (Life Technologies) according to manufacturer's instructions to evaluate cell proliferation. Finally, PBMCs were diluted in culture medium [DMEM supplemented with FBS (Sigma-Aldrich), antibiotics/antimycotics (Sigma-Aldrich) and β-mercaptoethanol (Sigma-Aldrich)] to a final concentration of $2 \times 10^6$ cells/mL. Then, $100 \mu$L was added to the designated wells of the u-bottom 96-well tissue-culture plate ($= 2 \times 10^5$ PBMCs/well). For the co-incubation samples, tpMSCs were thawed, washed and resuspended in culture medium to a final concentration of $2 \times 10^5$ tpMSCs/mL. The tpMSCs were plated at a 1:10 tpMSC:PMBC ratio (16, 39). The included negative control consisted of a PBMC culture from each horse (to assess baseline PBMC proliferation). As a positive control, PBMCs from each horse were stimulated with the mitogen concanavalin A (5 µg/mL; Sigma-Aldrich) (39, 48). Cultures were maintained for 4 days in a humidified incubator at 37°C and 5% CO2.

After the incubation period, PBMCs were collected, stained with 7-aminoactinomycine D (7-AAD; 1:100; BioLegend) for discrimination of live and dead cells. In the viable population, the PBMC proliferation was analyzed using a flow cytometer (BD FACSCanto II, BD Biosciences).

**Flow Cytometric Crossmatch Assay**

Whole blood was allowed to clot at room temperature for at least two h. Following centrifugation, serum was collected, heat-inactivated at 56°C for 30 min and cryopreserved at $-20^\circ$C until further analysis.

The FCCA was adapted to previously described methods (15, 49). Briefly, the vials containing the tpMSCs were thawed, counted, suspended to a suitable concentration and blocked
with goat serum to decrease non-specific antibody binding. The tpMSCs were mixed with the heat-inactivated recipient serum and stained after centrifugation using a fluorescent secondary antibody (Alexa Fluor 647 goat anti-horse IgG, 1:100; Jackson ImmunoResearch) targeting horse IgG antibodies bound to the tpMSCs. The assay negative control consisted of tpMSCs incubated with only the secondary antibody. As a positive control, tpMSCs were incubated with heat-inactivated serum derived form a hyperimmunized horse with a known high anti-BSA antibody binding before staining with the secondary antibody. After incubation, the samples were centrifuged, resuspended in flow stain buffer and stained with 7-AAD for flow cytometric analysis. The hyperimmunized horse suffered from multiple naturally occurring musculoskeletal diseases and was repeatedly treated intralesionally, intra-articularly and systemically (vena jugularis) with a minimal treatment interval of 2 weeks, resulting in increased IgG antibody levels. Therefore, the serum derived from this horse could be used as a positive control for the current assay.

Based on the results of the previous analysis, this protocol was also executed on the serum derived from the eight horses with a surgically induced SDFT lesion to detect alloantibodies against equine epithelial-like stem cells [EpSCs (50)] and commercially available equine sarcoïd cells (E42-02/RI; Friedrich-Loeffler-Institut) before and two weeks after a single tpMSC treatment (Study 1).

The alloantibody response was considered positive when an antibody binding of >15% was observed (15).

**Anti-BSA Antibody ELISA**

This assay was performed as previously described (15, 49). Briefly, a 96-well ELISA plate (PerkinElmer Life and Analytical Science) was coated with 100 µL BSA (1 µg/well; Sigma-Aldrich) in a carbonate-bicarbonate buffer (63.5 mM carbonate, pH 9.6) overnight at 4°C. Then 100 µL of 1% rabbit serum albumin (Sigma-Aldrich) in phosphate buffered saline (PBS; Sigma-Aldrich) was added to block. After incubation at 37°C for 1 h, wells were washed with PBS-Tween (Sigma-Aldrich) once for 10 min and then 6 times briefly. Then, 100 µL of test serum (diluted 1:100 in wash buffer) was added to each well. Each sample was plated in duplicate. Known negative (PBS and fetal horse serum) and high positive samples (horse with a known high anti-BSA antibody binding) were run as assay controls. Plates were incubated at 37°C for 1 h and washed as described above. Next, 100 µL of rabbit anti-equine IgG H&L-HRP (diluted 1:100,000; Abcam) was added to each well. Plates were incubated at 37°C for 1 h and subsequently washed as described above. A colorimetric reaction was initiated by adding 100 µL of TMB peroxidase substrate (KPL) to each well. Plates were incubated at room temperature in the dark. The colorimetric reaction was stopped by adding 100 µL of 2N H₂SO₄ (Sigma-Aldrich). The plates were read at 450 nm on a microplate reader (Victor 2030 Reader, PerkinElmer Life and Analytical Science). Fold increase in color relative to the negative control was determined for each sample. Samples were considered negative for anti-BSA antibodies if they displayed a fold increase < 2 compared to the negative control (15).

**Determination of Bovine Papillomavirus (BPV)**

BPV is a well-known pathogen associated with the development of equine sarcoids (11). To check if the commercially available sarcoïd cell-line is correctly positive for BPV and to evaluate a potential relationship between the elevated antibody response and the presence of BPV on the EpSCs and MSCs, a PCR was performed on the sarcoïd cell line, EpSC line and MSCs derived from the tpMSC donor to evaluate for presence of BPV-1 and BPV-2 DNA. DNA was extracted from MSCs, equine EpSCs and equine sarcoïd cells. Samples were thawed, supernatant was removed after centrifugation and the pellet was resuspended in PBS (Sigma-Aldrich). Subsequently, cells were lysed using proteinase K and lysis buffer (DNeasy Blood and Tissue Kit; Qiagen) and DNA was extracted using a commercially available kit (DNeasy Blood and Tissue Kit; Qiagen). After extraction, DNA was mixed with equine specific primers and probes (Table 1) and qPCR (Bio-Rad), after which polymerase chain reaction (PCR) was performed. The primers needed to amplify BPV are BPV+1 and BPV-1. The specific probes BPV type 1 and BPV type 2 are necessary for the detection of BPV-1 and/or BPV-2. Gene expression was analyzed on the CFX96 Real-time PCR Detection System (Bio-Rad). Interferon beta (IFN-β) was used as an internal control (house-keeping gene). The primers needed to amplify IFN-β are IFN-β-F and IFN-β-R (Table 1). The specific probe IFN-β allows detection of the IFN-β gene.

**Statistical Analysis**

**Mixed Lymphocyte Reactions**

**Study 1 (Single tpMSC Treatment)**

The fold change of each coculture/positive control was compared to the negative control. Therefore, the negative control was set to 1 and a mixed model was fitted. The Bonferroni correction for multiple comparisons was applied, setting the significance level at 0.025 (0.05/2).

**Study 2 (Repeated tpMSC Treatment)**

The normal distribution of the data was checked using the Shapiro-Wilk test. Normally distributed data were analyzed using the independent samples T-Test. P-values < 0.05 were considered statistically significant.

**Flow Cytometric Crossmatch Assay**

The normal distribution of the data was checked using the Shapiro-Wilk test. Normally distributed data were analyzed using the paired samples T-Test and not normally distributed data by the Wilcoxon Signed Rank Test. P-values < 0.05 were considered statistically significant.

**RESULTS**

**Isolation and Characterization of MSCs**

The cells displayed all properties to be characterized as MSCs (51). Briefly, they were plastic-adherent, trilineage differentiation towards osteoblasts, chondroblasts and adipocytes was successful and MSCs were positive for CD29 (100%), CD44 (100%),
TABLE 1 | Sequences and accession numbers of BPV-1, BPV-2 and IFN-β primers and probes.

| Gene       | Sequence                  | Accession number |
|------------|---------------------------|------------------|
| BPV+1 primer F | AATC0GGTGAGCAACCTTT         | X02346          |
| BPV-1 primer R | TGCTCTCCATCCTCTTTCA       | M20219          |
| BPV type 1 probe (FAM)CGTCAATCAGGTCTAAACGCCC(BHQ1) | M14546          |
| BPV type 2 probe (TEXAS RED)TCAACCAGGTCTAAAGGCC(BHQ2) | M20219          |
| IFN-β-F primer F | AGGTGGATCCTCCCAATGG       | M14546          |
| IFN-β-R primer R | CGAAGCAAGTCTAGTCAAGAAGA   | M14546          |
| IFN-β probe (FAM)CCTGCTGTGTTTCTCCACCACG(GC(BHQ1) | M14546          |

FIGURE 1 | Mixed lymphocyte reaction assay. (A) In eight horses before and after a single tpMSC treatment, the tpMSC-PBMC coculture did not give rise to a significant increase in mean PBMC proliferation before and after a single tpMSC treatment compared to the negative control. No statistically significant difference was present between PBMC proliferation before and after treatment. (B) In six horses after a second tpMSC treatment, the mean PBMC proliferation percentage was significantly lower than the proliferation rate of the negative control samples. PBMCs, peripheral blood mononuclear cells; tpMSCs = tenogenic primed mesenchymal stem cells. *P-values ≤ 0.05.

CD90 (100%) and negative for CD45 (1%) and MHC-II (0%) (Supplementary Materials 1–3).

Modified Mixed Lymphocyte Reaction Study 1: Single tpMSC Treatment
The addition of tpMSCs to equine PBMCs did not give rise to a significant increase in mean PBMC proliferation before (PBMCs + tpMSCs; 4.2 ± 2.2%) and after a single tpMSC treatment (PBMCs + tpMSCs; 3.2 ± 1.4%) compared to the negative control (PBMCs; 3.2 ± 1.7% and 3.7 ± 1.5%, respectively). Moreover, no statistically significant difference was present between PBMC proliferation before and after treatment (Figure 1A).

Study 2: Repeated tpMSC Treatment
The mean PBMC proliferation percentage of cells from treated horses (PBMCs + tpMSCs; 1.5 ± 0.7%) was significantly lower than the proliferation rate of the negative control samples (PBMCs; 4.2 ± 2.5%) (P = 0.041) (Figure 1B).

Flow Cytometric Crossmatch Assay Study 1: Single tpMSC Treatment
The percentage antibody binding to tpMSCs obtained before (5.9 ± 2.7%) and after (7.5 ± 8.1%) treatment was similar to the negative control (4.0 ± 4.9%) for seven out of eight horses. For these seven horses, there was no significant difference between the antibody binding to tpMSCs before and after treatment (Figure 2A). One horse showed an elevated level of antibody binding after the treatment with tpMSCs (65.6%) (Figure 2B), which was further investigated. A retrospective investigation of the clinical data of this horse revealed it was diagnosed with an equine sarcoid. To evaluate potential cross-reactivity of the anti-tpMSC antibodies to other cell types an additional FCCA was performed using skin EpSCs and a sarcoid cell line. No significant increase in antibody binding to EpSCs and sarcoid cells was detected after treatment (4.1 ± 2.2% and 2.6 ± 0.8%) compared to before treatment (4.0 ± 3.7% and 2.2 ± 0.7%) in seven out of eight horses (Figures 2C,F). However, a remarkable increase in antibody response against the EpSCs and sarcoid cells after treatment (92.1% and 90.1%) was observed compared to before treatment (22.7% and 40.4%) in the horse with the equine sarcoid (Figures 2D,F).

Study 2: Repeated tpMSC Treatment
In the repeatedly treated horses, no alloantibodies against the tpMSCs could be detected in the equine serum after the second treatment (6.7 ± 3.7%) (Figure 3). From these horses, no baseline samples before treatment could be obtained for comparison.
Anti-BSA Antibody ELISA

In study 1, three out of eight horses had high preexisting anti-BSA antibody levels ranging from 6 to 17 times higher than the horses with no anti-BSA antibody titers before tpMSC administration, which is defined as a fold increase < 2 compared to the negative control (15). Four of the five horses did not show considerable changes in anti-BSA antibody levels when sampled before or after tpMSC administration. However, one of these five horses showed a 5 times higher antibody level after treatment (Figure 4A, H6).

In the horses that received a repeated tpMSC injection (study 2), four out of six had high anti-BSA antibody titers after two treatments and one horse had a slightly increased anti-BSA antibody titer (Figure 4B, H11).

Bovine Papillomavirus PCR

A PCR was performed on the sarcoid cell line, EpSC line and MSCs derived from the tpMSC donor to evaluate for presence of BPV-1 and BPV-2 DNA. A positive result was only obtained in the equine sarcoid cells (949,400 copies/µL), indicating that BPV was not the common denominator and the equine sarcoid cells were indeed a clinically relevant cell line (Table 2). All cell types were negative for BPV-2.

DISCUSSION

To the best of our knowledge, this is the first study in the equine species investigating cellular and humoral immunogenicity of single or repeated intralesional injections of equine allogeneic tenogenic primed peripheral blood-derived MSCs (tpMSCs) in horses suffering from tendon injuries. The absence of the cellular immune response was evaluated in a modified MLR assay resulting in a similar mean recipient PBMC proliferation when compared to the negative control. These results clearly indicate that allogeneic tpMSCs can be injected intralesional without the induction of a cellular immune response. Previously published
MLR results of allogeneic bone marrow-derived MSCs (BM-MSCs) co-cultured with equine PBMCs also described absence of the host’s cellular immune response (13, 37). In a comparable in vitro study, the cellular immunogenicity of autologous and allogeneic BM-MSCs was investigated (39). It was observed that the allogeneic MSCs did not generate a strong alloreactive T cell response. Additionally, an in vitro study reported by Ranera et al. shows that equine allogeneic BM-MSCs are able to suppress the proliferation of mismatched PBMCs (16). However, this was not the case with MHC-II positive BM-MSCs which elicited a significantly increased responder lymphocyte proliferation (32), indicating that immunogenicity investigations remain important when evaluating MSC treatment options (38, 39). Considering humoral immunogenicity, one out of eight horses which received a single local allogenic tpMSC treatment and none of the horses receiving repeated treatments had anti-tpMSC antibodies. This was observed by the absence of a significant difference between the antibody binding before and after treatment (Study 1) or between the negative control and after treatment (Study 2). One horse (Study 1; H6; 12.5%) had an elevated antibody binding to the tpMSCs after a single treatment and was found to also have an equine sarcoid [i.e. the most common dermatological neoplasm in horses (52)]. The results of the additional analyses revealed that the humoral immune response induced by tpMSC treatment showed cross-reaction with EpSCs, sarcoid cells and bovine xenoproteins (BSA). Furthermore, a pre-existing presence of antibodies against sarcoid cells and other cell types of the epidermal lineage (i.e. EpSCs) were observed in this single horse. Serum from the other seven horses revealed no such binding or changes in anti-BSA antibody levels before and after tpMSC treatment. If there are antibodies present against BSA, this should always be taken under consideration when treating patients with a cell-based therapy cultivated in culture media supplemented with BSA. If cross-reaction of these specific antibodies occurs with the applied cell therapy, this could lead to a humoral immune response against the treatment.

In the current study, different timepoints were used for the evaluation of the cellular and humoral immune response. For the humoral immune response, it has been reported that the highest antibody peak after a single treatment is expected two weeks after treatment (53). Therefore, blood was sampled two weeks after the single treatment in the first study for the humoral immune response. When administering multiple injections, it has been reported that the antibody peak remains high from one week after the second treatment administration onwards (53). Therefore, blood was drawn six to eight weeks after the last treatment of the repeatedly treated horses from the second study. Considering the cellular immune response, lymphocyte responses and memory
cells are shown to persist on a long-term (54, 55). Therefore, the blood collection at the end of the first study could also be used to perform the mixed lymphocyte reaction assay. For the repeated injected horses, the blood collection performed at week 6–8 to investigate the humoral immune response was also used to perform the mixed lymphocyte reaction.

Additionally, BPV is a well-known pathogen associated with the development of equine sarcoïds (11). As a result of the PCR analysis for the detection of BPV DNA in MSCs, EpSCs and a sarcoïd cell line, a positive result was only obtained in the sarcoïd line, indicating BPV was not the common denominator and the sarcoïd cell line was indeed a relevant cell line of an in life sarcoïd. Based on current results, it remains unclear whether this could be related to the presence of a naturally occurring equine sarcoïd in one sero-converting horse or if it is an individual non-specific immune response against one or several different (xeno)antigens. Despite the occurrence of the non-specific immune response in one horse, a previous study performed by our group including these horses revealed no clinical abnormalities and promising results of the tpMSC treatment (46). Owens et al., reported an anti-BM-MSC antibody response in 37% of the horses receiving an allogeneic treatment (15). In the latter in vivo study, a total of 19 horses received fully unmatched allogeneic adipose tissue-derived MSCs or BM-MSCs via intravenous, intra-arterial, intra-tendon and intraocular routes (range of 25 to 80 million MSCs per injection). The same flow cytometric crossmatch assay was used to detect alloantibodies. The high MSC dosage in this study may contribute to the higher alloantibody response when compared to the current investigation. Additionally, Barrachina et al., reported alloantibody production in case of a repeated intravenous injection of equine allogeneic MSCs has been described for single (two consecutive) allogeneic tpMSC treatment in horses with tendon injury, confirming the low immunogenic properties of these cells in these two studies. In the future, a larger field study should confirm these findings and support the safe use of equine allogeneic tpMSCs as a promising therapeutic for horses suffering from naturally occurring tendon injuries.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Independent Ethics Committee approved by the Flemish Government (permit number: LA1700607). Written informed consent was obtained from the owners for the participation of their animals in this study.

**AUTHOR CONTRIBUTIONS**

JSp, LV, and ED conceived the study and planned the design. Mixed lymphocyte reaction and alloantibody assays were performed by ED and LV. The anti-BSA antibody assays were performed by ED and LV. The authors suggested this could be an alloantigen-directed cytotoxic response. Although it has been described that repeated administration of allogeneic peripheral blood-derived tpMSCs is indicated in some clinical cases to improve the outcome of tendon injuries (24, 25), in depth research on the cellular and humoral immunogenicity of repeated allogeneic MSC treatments is presently lacking, emphasizing the importance of current research.

The performed study comes with some limitations. First, from the horses with naturally occurring tendon lesions only serum after the second tpMSC injection and no serum before the first or second tpMSC injection was available. Therefore, baseline values could not be included for these horses. However, these time points were investigated in the horses receiving a single tpMSC treatment. Additionally, since these horses are client-owned and not involved in a clinical trial with prescheduled visits, no standardized follow-up time points were included as in Study 1. Second, considering the lack of positive results in the MLR assay, the use of PBMCs derived from the allogeneic donor could be included as a positive control and autologous PBMCs as a negative control to support the results. This way the PBMC proliferation induced by allogeneic cells can be evaluated as positive control in addition to the concanavalin A stimulation. However, a previous study performed by our group showed that native MSCs are able to suppress concanavalin A stimulated PBMCs (58). This data shows that if there is a reaction between the MSCs and PBMCs in the co-culture, this can be detected using this assay. Third, both studies consisted of respectively 8 or 6 horses, which is a rather small sample size. Therefore, these results should be confirmed in a larger field study. Fourth, the equine leukocyte antigen (ELA) haplotype from both donor and recipient horses was unknown. It has been reported that specific antibodies can be produced when donor and recipient are ELA-mismatched, but not when they are ELA-matched (33, 34, 40). It is thus possible that anti-ELA antibodies are produced when donor and recipient are ELA-mismatched. However regarding the clinical applicability of MSCs it is not always possible in the field to only treat ELA-matched recipients when an MSC treatment is indicated.

It can be concluded that, except for one horse, the administration of tpMSCs did not induce a cellular or humoral immune response following an intraslesional single or repeated (two consecutive) allogeneic tpMSC treatment in horses with tendon injury, confirming the low immunogenic properties of these cells in these two studies. In the future, a larger field study should confirm these findings and support the safe use of equine allogeneic tpMSCs as a promising therapeutic for horses suffering from naturally occurring tendon injuries.
performed by MP and LDa. Statistical analysis was done by LDu and LV. ED wrote the first draft of the manuscript. JSp, SB, JSa, LV, AM, FP, and KC provided supervision and critical review of the manuscript. All authors read and approved the final manuscript.

**FUNDING**

This research was funded both by BIVMB supported by a grant from the Flanders Innovation & Entrepreneurship (Vlaio project number: HBC.2018.0182).

**REFERENCES**

1. Smith RKW, Werling NJ, Dakin SG, Alam R, Goodship AE, Dudia J. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy. PLoS ONE. (2013) 8:1–14. doi: 10.1371/annotation/a30a8b87-9804-4510-b0a8-36c6c009790.

2. Conze P, Van Schie HT, Weeren RV, Staszyk C, Conrad S, Skutella T, et al. Effect of autologous adipose tissue-derived mesenchymal stem cells on neovascularization of artificial equine tendon lesions. Regen Med. (2014) 9:743–57. doi: 10.2217/reme.14.55.

3. Romero A, Barrachina L, Ranera B, Remacha AR, Moreno B, de Blas I, et al. Comparison of autologous bone marrow and adipose tissue derived mesenchymal stem cells, and platelet rich plasma, for treating surgically induced lesions of the equine superficial digital flexor tendon. Vet J. (2017) 224:76–84. doi: 10.1016/j.tvjl.2017.04.005.

4. Bertoni L, Brantly T, Jacquet S, Desancé M, Desquilbet L, Rivory P, et al. Intra-articular injection of 2 different dosages of autologous and allogeneic bone marrow- and umbilical cord-derived mesenchymal stem cells triggers a variable inflammatory response of the fetlock joint on 12 sound experimental horses. Stem Cells Int. (2019) 9431894. doi: 10.1155/2019/9431894.

5. Shokry M, Mostafa A, Tohamy A, El-Sharkawi M. Autologous mesenchymal stem cells for treatment of acute superficial digital flexor tenonitis in athletic horses- a clinical study of 1 5 cases. Pferdeheilkunde. (2020) 36:43–8. doi: 10.21836/PEM20200107.

6. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. (2002) 46:704–13. doi: 10.1002/art.10118.

7. Nie Y, Lau CS, Lie AK, Chan GC, Mok MY. Defective phenotype of mesenchymal stem cells in naturally occurring tendinopathy. Int J Orthop Res. (2013) 20:2384–404. doi: 10.1016/j.iromr.2013.02.012.

8. Choudhery MS, Khan M, Mahmood R, Mehmood A, Khan SN, Riazuddin S. Bone marrow derived mesenchymal stem cells from aged mice have reduced wound healing, angiogenesis, proliferation and anti-apoptosis capabilities. Cell Biol Int. (2012) 36:747–53. doi: 10.1002/cbi.20110183.

9. Marycz K, Kornicka K, Basinska K, Czyrek A. Equine metabolic syndrome affects viability, senescence, and stress factors of equine adipose-derived mesenchymal stem cells: new insights into EquASCS isolated from EMS horses in the context of their aging. Oxid Med Cell Longev. (2016) 2016:4710326. doi: 10.1155/2016/4710326.

10. Marycz K, Kornicka K, Mareziak M, Golonka P, Nicpochi J. Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy. J Cell Mol Med. (2016) 20:2384–404. doi: 10.1111/jcmm.12932.

11. Chambers G, Ellsmore VA, O’Brien PM, Reid SWJ, Love S, Campo MS, et al. Association of bovine papillomavirus with the equine sarcoid. J Gen Virol. (2003) 84:1055–62. doi: 10.1099/vir.0.18947-0.

12. Ricco S, Renzi S, Del Bue M, Conti V, Merli E, Ramoni R, et al. Allogeneic adipose tissue-derived mesenchymal stem cells in combination with platelet rich plasma are safe and effective in the therapy of superficial digital flexor tenonitis in the horse. Int J Immunopathol Pharmacol. (2013) 26:661–8. doi: 10.3394/jipf.2013.26.2.15026.

13. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther. (2015) 6. doi: 10.1186/s13287-015-0173-5.

14. Van Loon VJF, Scheffer C JW, Genn HJ, Hoogendoorn AC, Greve JW. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders. Vet Q. (2014) 34:92–7. doi: 10.1080/01651526.2014.949390.

15. Owens SD, Kol A, Walker NJ, Borjesson DL. Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses. Stem Cells Int. (2016) 5830103. doi: 10.1155/2016/5830103.

16. Ranera B, Antczak D, Miller D, Doroshenkovka T, Ryan A, McHlraith CW, et al. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes. Equine Vet J. (2016) 48:253–60. doi: 10.1111/evj.12414.

17. Brandt L, Schubert S, Scheibe P, Brehm W, Franzen J, Gross C, et al. Tenogenic properties of mesenchymal progenitor cells are compromised in an inflammatory environment. Int J Mol Sci. (2018) 19:1–26. doi:10.3390/ijms19092549.

18. Harris MT, Butler DL, Boivin GP, Florer BJ, Schantz EJ, Wenstrup RJ. Mesenchymal stem cells used for rabbit tendon repair can form ectopic bone and express alkaline phosphatase activity in constructs. J Orthop Res. (2004) 22:998–1003. doi: 10.1016/j.orthres.2004.02.012.

19. Dresler MR, Butler DL, Boivin GP. Effects of age on the repair ability of mesenchymal stem cells in rabbit tendon. J Orthop Res. (2005) 23:287–93. doi: 10.1016/j.jorhres.2004.06.017.

20. Fang Z, Zhu T, Shen WL, Tang QM, Chen JL, Yin Z, et al. Transplantation of fetal instead of adult fibroblasts reduces the probability of ectopic ossification during tendon repair. Tissue Eng : Part A. (2014) 20:1815–26. doi: 10.1089/ten.tea.2013.0296.

21. Shojaee A, Parham A. Strategies of tenogenic differentiation of equine stem cells for tendon repair: Current status and challenges. Stem Cell Res Ther. (2019) 10:1–13. doi: 10.1186/s13287-019-1291-0.

22. Gomiero C, Bertolotti G, Martinello T, Van Bruaene N, Broeckx SV, Patruno M, et al. Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology. Vet Res Commun. (2016) 40:39–48. doi: 10.1007/s11959-016-9652-y.

23. Broeckx S, Zimmerman M, Aerts D, Seys B, Suls M, Mariën T, et al. Tenogenesis of equine peripheral blood-derived mesenchymal stem cells: In vitro versus In vivo. J Tissue Eng Sci S11. (2012) 1–6. doi: 10.4172/2157-7552.S11-001.

24. Vandenberghhe A, Broeckx SY, Beerts C, Seys B, Zimmerman M, Verweire I, et al. Tenogenically induced allogeneic mesenchymal stem cells for the treatment of proximal suspensory ligament desmitis in a horse. Front Vet Sci. (2015) 2. doi: 10.3389/fvets.2015.00049.

25. Beerts C, Suls M, Broeckx SY, Seys B, Vandenberghhe A, Deleerq J, et al. Tenogenically induced allogeneic peripheral blood mesenchymal stem cells in allogeneic platelet-rich plasma. 2-year follow-up after tendon or ligament treatment in horses. Front Vet Sci. (2017) 4:1–10. doi: 10.3389/fvets.2017.00158.
26. Broeckx S, Suls M, Beerts C, Vandenberghe A, Seys B, Wuerzt-Kozak K, et al. Allogenic mesenchymal stem cells as a treatment for equine degenerative joint disease: a pilot study. Curr Stem Cell Res Ther. (2014) 9:497–503. doi: 10.2174/1574888X09666140826110601

27. Broeckx SY, Spass HA, Chiers K, Duchateau L, Van Hecke L, Van Brantegem L, et al. Equine allogeneic chondrogenic induced mesenchymal stem cells: a GCP target animal safety and biodistribution study. Res Vet Sci. (2018) 117:246–54. doi: 10.1016/j.rvsc.2017.12.018

28. Broeckx SY, Martens AM, Bertone AL, Van Brantegem L, Duchateau L, Van Hecke L, et al. The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study. Equine Vet J. (2019) 51:787–94. doi: 10.1111/eve.13089

29. Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T, Ferguson SJ, et al. Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS ONE. (2014) 9:1–11. doi: 10.1371/journal.pone.0085917

30. Ardanaz N, Vázquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, et al. Immunological response to the administration of mesenchymal stem cells in an equine experimental model: Effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints. BMC Vet Res. (2016) 12:1–9. doi: 10.1186/s12917-016-0692-x

31. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R, et al. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther. (2014) 5:1–13. doi: 10.1186/sctrr402

32. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MB, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther. (2015) 4:1–11. doi: 10.1186/s13287-015-0053-x

33. Barrachina L, Cequier A, Romero A, Vitoria A, Zaragoza P, Vázquez FJ, et al. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: Effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility. Stem Cell Res Ther. (2010) 1:1–12. doi: 10.1186/scrt021

34. Noronha NDC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, et al. Inflammatory response to the administration of mesenchymal stem cells in a surgically induced superficial digital flexor tendon lesion model. Front Vet Sci. (2021) 8:6166. doi: 10.3389/fvets.2021.61441

35. Spass HA, De Schauwer C, Cornillie F, Meyer E, Van Soom A, Van De Walle GR. Culture and characterisation of equine peripheral blood mesenchymal stem cells. Cell Stem Cell. (2013) 13:107–13. doi: 10.1016/j.stem.2012.05.006

36. Muul LM, Heine G, Silvín C, James SP, Candotti F, Radbruch A, et al. Measurement of proliferative responses of cultured lymphocytes. Curr Protoc Immunol. (2011) 94:7.10.1–26. doi: 10.1002/0471142735.im071094

37. Van Hecke L, Magri C, Duchateau L, Beerts C, Geburek F, Suls M, et al. Repeated intra-articular administration of equine allogeneic peripheral blood-derived mesenchymal stem cells does not induce a cellular and humoral immune response in horses. Vet Immunol Immunopathol. (2021) 239:110306. doi: 10.1016/j.vetimm.2021.110306

38. Broeckx SY, Maes S, Martínez T, Ardanaz N, Chiers K, Mariën T, et al. Equine epidermic A source of epithelial-like stem/progenitor cells with in vitro and in vivo regenerative capacities. Stem Cells Dev. (2014) 23:1134–48. doi: 10.1089/scd.2013.0203

39. Dominici M, Le Blanc K, Mueller L, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Int. Soc. Cell Therapy. (2006) 8:315–7. doi: 10.1080/1465324060855905

40. Bogaert E, Martens A, Depoorter P, Gathuks F, Equine sarcoids - Part 1: clinical presentation and epidemiology. Vlaams Diergeneesk Tijdschr. (2008) 77:2–9.

41. Murphy KM. Dynamics of adaptive immunity. In Janeway’s Immunobiology (GarlandScience). (2012) p. 429.

42. Cabon Q, Febre M, Gomez N, Cachon T, Pillard P, Carozzo C, et al. Long-term safety and efficacy of single or repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for managing pain and lameness in moderate to severe canine osteoarthritis without anti-inflammatory pharmacological support. Pi. Front Vet Sci. (2019) 6:1–14. doi: 10.3389/fvets.2019.00010

43. Magri C, Schramme M, Febre M, Caumin LF, Labadie F, Saulnier N, et al. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: a clinical pilot study. PLoS ONE. (2019) 14:1–16. doi: 10.1371/journal.pone.0221317

44. Paillot R, Marcellaud Pitel C, D’ablon X, Prinston S. Equine vaccines: how, when and why? Report of the vaccineinology session, french equine veterinarians association, 2016, reims. Vaccines. (2017) 5:46. doi: 10.3390/vaccines5040046

45. Gershwin LJ, Netherwood KA, Norris MS, Behrens NE, Shao MX, Equine IgE responses to non-viral vaccine components. Vaccine. (2012) 30:7615–20. doi: 10.1016/j.vaccine.2012.10.029

46. Depuydt E, Broeckx SY, Van Hecke L, Chiers K, Van Brantegem L, Van Schie H, et al. The evaluation of equine allogeneic tenogenic primed mesenchymal stem cells in a surgically induced superficial digital flexor tendon lesion model. Front Vet Sci. (2021) 8:6166. doi: 10.3389/fvets.2021.61441
Conflict of Interest: JHS declares competing financial interests as shareholder in Boehringer Ingelheim Veterinary Medicine Belgium (BIVMB) at the time of the study. SB, JHS, ED, and LV were all employed by BIVMB at the time of the study. The content of this manuscript contains a stem cell product under development (RenuTend®) owned and patented by BIVMB.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.